Proto Script Pharmaceutical

Proto Script Pharmaceutical Net Debt/Equity

The Net Debt to Equity Ratio of Proto Script Pharmaceutical (PSCR) as of Nov 1, 2026 is -1.06. In the previous year, Net Debt to Equity Ratio was 0.43 — a change of -344.19% (lower).

Net Debt/Equity

-1.06

YoY

-344.19%

Last updated:

Net Debt to Equity Ratio of Proto Script Pharmaceutical is 2016 -1.06 . Net Debt to Equity Ratio of Proto Script Pharmaceutical was 2015 0.43 . It decreases by -344.19% lower compared to the previous year.

The Proto Script Pharmaceutical Net Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/Equity
Date
Net Debt/Equity
Jan 1, 2015
0.43 USD
Jan 1, 2016
-1.06 USD
The Proto Script Pharmaceutical Net Debt/Equity history
YEARNet Debt/EquityYoY
-1.06-344.19%
0.43—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Proto Script Pharmaceutical Stock analysis

What does Proto Script Pharmaceutical do? Proto Script Pharmaceutical Corp is an American biotechnology company specializing in the development and manufacture of innovative, high-quality drugs. The company is focused on researching new breakthrough technologies in drug manufacturing to find potential cures and treat diseases. Their business model is based on producing medications that are highly effective and of high quality while also being cost-effective and patient-friendly. They collaborate closely with biotechnology companies and academic institutions to acquire the best technologies and develop effective and innovative drugs. They have products in the areas of neurology, endocrine health, and oncology. They have also entered into partnerships with other companies to expand and further develop their products. Overall, Proto Script Pharmaceutical Corp is a groundbreaking company in the biotechnology field with decades of experience in drug development and a commitment to improving the lives of millions of people worldwide. Proto Script Pharmaceutical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Proto Script Pharmaceutical stock

Net Debt to Equity Ratio of Proto Script Pharmaceutical is -1.06 in 2016.

Net Debt to Equity Ratio of Proto Script Pharmaceutical changed from 0.43 to -1.06, representing a -344.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Equity Ratio Proto Script Pharmaceutical since 2006 – with annual values, charts, and detailed analysis.

Net Debt/Equity adjusts the debt-to-equity ratio by subtracting cash from total debt. It provides a more accurate picture of actual leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Equity Ratio's Proto Script Pharmaceutical with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Proto Script Pharmaceutical

All Key Metrics — Proto Script Pharmaceutical